Valeant Pharma (VRX) Sees Solid Upside
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Wall Street closes higher as investors digest earnings, megacap outlook
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Trump presidency could prove a salve for pharma merger deals
November 11, 2016 1:03 AM ESTBy Carl O'Donnell
NEW YORK (Reuters) - Biotechnology companies, whose U.S. shares soared Wednesday after Republican Donald Trump's presidential election, may soon see another benefit: an uptick in biotech M&A.
A potential influx of foreign cash and improved stock valuations under the Trump administration would likely boost dealmaking in the industry, which has been anemic ever since political rhetoric against high drug prices picked up late last year, industry analysts and investment bankers said.
That could mean renewed interest in some prime targets of takeover speculation, from cancer drug specialists like Tesaro Inc... More
Valeant may seek to clean up its name by changing it: Ackman
November 10, 2016 7:14 PM ESTBy Carl O'Donnell and Svea Herbst-Bayliss
NEW YORK (Reuters) - Valeant Pharmaceuticals International Plc (NYSE: VRX), the drugmaker that became a poster child for high drug prices during the U.S. election season, may change its name to help boost its reputation, board member and top investor William Ackman told CNBC on Wednesday.
A name change would be the latest effort by the company to break from its past, after hiring a new chief executive, overhauling the board and exploring billions of dollars in asset sales to pay down a $30 billion... More